[go: up one dir, main page]

BRPI0411673A - composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto - Google Patents

composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0411673A
BRPI0411673A BRPI0411673-9A BRPI0411673A BRPI0411673A BR PI0411673 A BRPI0411673 A BR PI0411673A BR PI0411673 A BRPI0411673 A BR PI0411673A BR PI0411673 A BRPI0411673 A BR PI0411673A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
diseases
Prior art date
Application number
BRPI0411673-9A
Other languages
English (en)
Inventor
Jian J Chen
Ben C Asken
Kaustav Biswas
Jennifer N Chau
Derin C D Amico
Scott Harried
Thomas Nguyen
Wenyuan Qian
Jiawang Zhu
Christopher H Fotsch
Nianhe Han
Aiwen Li
Qingyian Liu
Nobuko Nishimura
Rana Nomak
Tanya Peterkin
Babak Riahi
Kevin Yang
Chester Chenguang Yuan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0411673A publication Critical patent/BRPI0411673A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)

Abstract

"COMPOSTO, SAL FARMACEUTICAMENTE ACEITáVEL, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTOS". Compostos selecionados são efetivos para tratamento de dor e doenças, como doenças mediadas com inflamação. A invenção compreende compostos, análogos, pró-drogas e derivados inéditos farmaceuticamente aceitáveis dos mesmos, composições farmacêuticas e métodos para profilaxia e tratamento de doenças e de outras malignidades ou condições que envolvem dor, inflamação, e análogos. A presente invenção também se refere a processos para preparar referidos compostos e também a intermediários úteis em referidos processos.
BRPI0411673-9A 2003-06-20 2004-06-21 composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto BRPI0411673A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48030303P 2003-06-20 2003-06-20
PCT/US2004/019935 WO2005061467A2 (en) 2003-06-20 2004-06-21 Piperazine derivatives as bradykinin antagonists

Publications (1)

Publication Number Publication Date
BRPI0411673A true BRPI0411673A (pt) 2006-08-08

Family

ID=34710016

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411673-9A BRPI0411673A (pt) 2003-06-20 2004-06-21 composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto

Country Status (18)

Country Link
US (2) US7393852B2 (pt)
EP (1) EP1656355B1 (pt)
JP (1) JP2007516176A (pt)
KR (1) KR20060036399A (pt)
CN (1) CN1849121A (pt)
AT (1) ATE388708T1 (pt)
AU (1) AU2004303757B2 (pt)
BR (1) BRPI0411673A (pt)
CA (1) CA2529314A1 (pt)
DE (1) DE602004012418T2 (pt)
ES (1) ES2302079T3 (pt)
IL (1) IL172419A0 (pt)
IS (1) IS8175A (pt)
MX (1) MXPA05013469A (pt)
NO (1) NO20060278L (pt)
RU (1) RU2006101541A (pt)
WO (1) WO2005061467A2 (pt)
ZA (1) ZA200600579B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040073617A1 (en) * 2000-06-19 2004-04-15 Milliken Walter Clark Hash-based systems and methods for detecting and preventing transmission of unwanted e-mail
US7328349B2 (en) 2001-12-14 2008-02-05 Bbn Technologies Corp. Hash-based systems and methods for detecting, preventing, and tracing network worms and viruses
US7200105B1 (en) * 2001-01-12 2007-04-03 Bbn Technologies Corp. Systems and methods for point of ingress traceback of a network attack
US7393852B2 (en) * 2003-06-20 2008-07-01 Amgen Inc. Piperazine derivatives and methods of use
AU2005275036A1 (en) * 2004-07-15 2006-02-23 Amgen Inc. 1,2,3,4-tetrahydropyrazin-2-yl acetamides and their use as bradykinin antagonists for the treatment of inflammation related disorders
US20060217362A1 (en) * 2004-12-29 2006-09-28 Tung Jay S Novel compounds useful for bradykinin B1 receptor antagonism
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
US8059551B2 (en) * 2005-02-15 2011-11-15 Raytheon Bbn Technologies Corp. Method for source-spoofed IP packet traceback
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
ATE538100T1 (de) 2008-07-15 2012-01-15 Hoffmann La Roche Aminotetrahydroindazoloessigsäuren
PE20110703A1 (es) * 2008-11-17 2011-10-13 Hoffmann La Roche Acidos naftilaceticos
BRPI0921254A2 (pt) * 2008-11-17 2018-10-23 Hoffmann La Roche acidos naftilacéticos
JP5373104B2 (ja) * 2008-11-17 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｒｔｈ２アンタゴニスト又は部分アゴニストとして使用されるナフチル酢酸
EP2666765B1 (en) 2010-06-15 2017-01-04 Grünenthal GmbH Process for the preparation of substituted 3-(1-amino-2-methyl-pentane-3-yl)phenyl compounds
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
US9000044B2 (en) 2012-02-28 2015-04-07 Hoffmann-La Roche Inc. Substituted naphthylacetic acids
US9932424B2 (en) * 2014-11-14 2018-04-03 Warner Babcock Institute For Green Chemistry, Llc Compositions and methods for compatibilizing fluorinated materials in nonfluorinated solvent systems
CN117924208A (zh) * 2018-01-19 2024-04-26 赛特凯恩蒂克公司 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2098702A1 (en) 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
DE60001535T2 (de) 1999-12-10 2003-10-02 Pfizer Inc., New York Substituierte 1,4-Dihydropyridinverbindungen zur Verwendung als Bradykininantagonisten
BR0112580A (pt) 2000-07-19 2003-06-17 Hoffmann La Roche Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos, processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos
WO2002099388A2 (en) 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepine bradykinin antagonists
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
CA2501801A1 (en) 2002-10-10 2004-04-22 Elan Pharmaceuticals, Inc. Sulfonylbenzodiazepinone acetamides as bradykinin antagonists
US6908921B2 (en) 2002-12-13 2005-06-21 Merck & Co., Inc. Quinoxalinone derivatives as bradykinin B1 antagonists
US20060178370A1 (en) 2003-03-18 2006-08-10 Mark Bock Ketopiperazine derivatives as bradykinin antagonists
JP2006522835A (ja) 2003-04-10 2006-10-05 アムジェン インコーポレイテッド 環状アミン誘導体およびブラジキニンによって媒介される炎症関連障害の処置におけるそれらの使用
EP1631542A1 (en) 2003-04-10 2006-03-08 Amgen, Inc. Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
US7393852B2 (en) * 2003-06-20 2008-07-01 Amgen Inc. Piperazine derivatives and methods of use
AU2005275036A1 (en) * 2004-07-15 2006-02-23 Amgen Inc. 1,2,3,4-tetrahydropyrazin-2-yl acetamides and their use as bradykinin antagonists for the treatment of inflammation related disorders

Also Published As

Publication number Publication date
EP1656355A2 (en) 2006-05-17
DE602004012418T2 (de) 2008-06-19
DE602004012418D1 (de) 2008-04-24
US7393852B2 (en) 2008-07-01
IL172419A0 (en) 2006-04-10
IS8175A (is) 2005-12-12
JP2007516176A (ja) 2007-06-21
US20090054460A1 (en) 2009-02-26
WO2005061467A3 (en) 2006-06-01
KR20060036399A (ko) 2006-04-28
CA2529314A1 (en) 2005-07-07
CN1849121A (zh) 2006-10-18
AU2004303757B2 (en) 2009-07-23
ES2302079T3 (es) 2008-07-01
NO20060278L (no) 2006-03-15
ATE388708T1 (de) 2008-03-15
MXPA05013469A (es) 2006-03-09
US20050014749A1 (en) 2005-01-20
RU2006101541A (ru) 2006-06-10
EP1656355B1 (en) 2008-03-12
WO2005061467A2 (en) 2005-07-07
ZA200600579B (en) 2007-04-25
AU2004303757A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
BRPI0411673A (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto
ATE404552T1 (de) Substituierte isochinolinderivate und anwendungsverfahren
TW200716596A (en) Substituted amide derivatives and methods of use
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
PT1448564E (pt) Composto do tipo indolizina substituidos e metodos de utilizacao
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
DK1309589T3 (da) Ureaforbindelser og anvendelsesfremgangsmåder
EE200300324A (et) Asendatud alküülamiini derivaadid ja nende kasutamismeetodid
MY167135A (en) Fused heterocyclic derivatives and methods of use
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
WO2008079291A3 (en) Substituted heterocycles and methods of use
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2002068406A3 (en) Substituted amine derivatives and their use for the treatment of angiogenesis
WO2004007481A3 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2004092116A8 (en) Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
MXPA05010883A (es) Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina.
WO2006041888A3 (en) Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents
MX2007004279A (es) Triazoles y su uso como antagonistas del receptor b1 de bradiquinina.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]